Related Experiment Video

Updated: Jul 13, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

New approaches in systemic treatment of advanced colorectal cancer: the molecular targets era

Jaume Capdevila1, Guillermo Mendez, Teresa Macarulla

  • 1Vall d'Hebron University Hospital, Medical Oncology Department, Barcelona, Spain. jacapdevila@vhebron.net

Expert Review of Anticancer Therapy
|July 14, 2007
PubMed

Insights

Advanced colorectal cancer prognosis is poor, but new molecularly targeted therapies show promise. This review examines trials of monoclonal antibodies and tyrosine kinase inhibitors to optimize their use in treatment.

Area of Science:

  • Oncology
  • Medical research

Background:

  • Advanced colorectal cancer (CRC) still has a poor prognosis despite recent therapeutic, surgical, and diagnostic advancements.
  • Emerging molecularly targeted treatments aim to improve outcomes for advanced CRC patients.

Purpose of the Study:

  • To review key clinical trials of monoclonal antibodies and tyrosine kinase inhibitors in advanced colorectal cancer.
  • To assess the current landscape and future directions for targeted therapies in advanced CRC.

Main Methods:

  • Literature review of major clinical trials.
  • Analysis of studies involving monoclonal antibodies and tyrosine kinase inhibitors for advanced CRC treatment.

Main Results:

  • Monoclonal antibodies and tyrosine kinase inhibitors represent significant progress in targeted therapy for advanced CRC.
  • Ongoing research is crucial for optimizing the application and efficacy of these novel agents.

Conclusions:

  • Targeted therapies, including monoclonal antibodies and tyrosine kinase inhibitors, offer new hope for advanced colorectal cancer.
  • Further research and clinical trials are essential to refine treatment strategies and improve patient survival rates.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...